Editorial Comment
Editorial Comment to Psychotherapy combined with drug therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome: A randomized controlled trial
First published: 01 July 2018
No abstract is available for this article.
Conflict of interest
None declared.
References
- 1Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009; 73: 538–42.
- 2Magri V, Wagenlehner F, Perletti G et al. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J. Urol. 2010; 184: 2339–45.
- 3Shoskes DA, Nickel JC. Classification and treatment of men with chronic prostatitis/chronic pelvic pain syndrome using the UPOINT system. World J. Urol. 2013; 31: 755–60.
- 4Magistro G, Wagenlehner FM, Grabe M, Weidner W, Stief CG, Nickel JC. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur. Urol. 2016; 69: 286–97.
- 5Wang J, Liang K, Sun H, Li L, Wang H, Cao J. Psychotherapy combined with drug therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Int. J. Urol. 2018; 25: 710–5.
